Background and Purpose-Magnetic resonance imaging visible perivascular spaces in the centrum semiovale (CSO-PVS) have been associated with cerebral amyloid angiopathy (CAA 
1
PVS are filled with interstitial fluid, which contains plasma solutes and waste products from brain metabolism (including β-amyloid [Aβ]). Theoretical and animal models have suggested that interstitial fluid flow within PVS is largely driven by the blood flow in the associated vessel [2] [3] [4] and that these 2 flows follow opposite directions. 3, 5 The periarterial pathway is a main clearance mechanism for soluble Aβ, and it was shown to be defective in aging 6 and in the context of the 2 main disorders associated with amyloid accumulation in the brain: Alzheimer disease 2 and cerebral amyloid angiopathy (CAA). 6 CAA, in turn, may further impair interstitial fluid drainage by physically obstructing PVS at a cortical level, setting in motion a forward feedback loop. 7, 8 Thus, accumulating evidence supports the view that PVS dysfunction may be a strong determinant of Aβ build-up in Alzheimer disease/CAA.
PVS are usually microscopic and hence not visible on conventional magnetic resonance imaging (MRI);
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August 2018 presumably when PVS are dilated they become increasingly visible on neuroimaging. Increased MRI-visible PVS have been reported as a frequent feature in aging 9 and in relation to several pathological conditions. [10] [11] [12] [13] Extensive PVS may ultimately reflect a state of interstitial fluid stagnation, and be an indication of poor drainage of certain solutes toxic to the brain, such as Aβ species. In line with this hypothesis, 2 landmark radiological studies using different patient populations found a consistent association between increased PVS in the whole brain white matter (WM-PVS), and the centrum semiovale (CSO-PVS) in particular, and presence and number of strictly lobar hemorrhages, a putative marker of CAA. 14, 15 Also, high grade of CSO-PVS has been associated with higher total cortical retention of Pittsburgh B compound in a positron emission tomography study of nondemented elderly individuals, including cases with probable CAA. 16 Although these findings are potentially of great clinical interest, the association between increased CSO-PVS and neuropathologically-confirmed CAA has been explored only in 1 small study. 17 Therefore, it is still uncertain whether increased CSO-PVS are linked to the presence of CAA and, importantly, whether CSO-PVS may have a diagnostic role for CAA independent of strictly lobar hemorrhages, the most salient putative biomarker of the disease. 18, 19 One further point to consider when addressing the role of PVS dilation in CAA comes from a recent memory cohort study, which suggests that aging and hypertension, which had been linked to PVS dilation in the basal ganglia regions, 14, 15 could also contribute to dilation of CSO-PVS. 20 One way to overcome this potential overlap is to target younger individuals carrying hereditary forms of CAA, as the confounding effect of advanced age and long exposure to vascular risk factors is virtually avoided. To our knowledge, no neuroimaging studies on PVS have been conducted in hereditary CAA populations to date.
In this study, we aimed to confirm whether increased CSO-PVS may have an independent diagnostic role for CAA. For this purpose, we evaluated MRI-visible CSO-PVS in (1) a hospital-based cohort of elderly subjects having neuropathological assessment of CAA (sporadic CAA); and (2) a young cohort of carriers and noncarriers of the hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA-D) mutation, a pure early-onset cerebrovascular amyloidosis. In a second step, we assessed in the sporadic CAA cohort whether CSO-PVS could independently predict the presence of underlying CAA pathology even in the absence of any hemorrhagic lesions, including cerebral microbleeds.
Subjects and Methods
The data that support the findings of this study are available from the corresponding author on reasonable request.
Study Cohorts

Sporadic Cohort
We searched across data sets for patients seen at Massachusetts General Hospital (MGH) between 1997 and 2012 who were older than 55 years and had records of both brain MRI and neuropathological examination of the brain. We applied an exclusion algorithm to obtain a cohort of individuals having high-quality, complete MRI brain studies (including hemosiderin-specific sequences) and explicit CAA assessment. Details on inclusion/exclusion workflow are explicited in Figure 1 . A total of 63 individuals met criteria for inclusion.
Hereditary Cohort
Subjects were identified and selected via the HCHWA-D patient association in Katwijk (the Netherlands) and the outpatient clinic of the Department of Neurology of the Leiden University Medical Center based on DNA analysis for confirmation of the codon 693 mutation in the AβPP (amyloid-β precursor protein) gene. Twentysix DNA-proven HCHWA-D mutation carriers were included in the present study. These subjects had a mean age of 45.9 years (25th-75th percentile 35-55 years). We included both symptomatic (n=15) and presymptomatic (n=11) mutation carriers. Control subjects were recruited from relatives at risk for HCHWA-D but who tested genetically negative. Additional control subjects were recruited from subject spouses, relatives or friends, who also underwent genetic testing for inclusion. Twenty-eight controls were included in the present study. These subjects had a mean age of 47.5 years (25th-75th percentile 37-57 years).
Definition of Sporadic and Hereditary CAA Diagnosis
Sporadic CAA (Hospital-Based Cohort)
Brain pathology reports were reviewed by a neurologist blinded to radiological and clinical data (Dr Martinez-Ramirez). Specific studies for CAA detection included Congo red staining and β-amyloid immunostaining (DAKO) of paraffin-embedded sections of neocortex and leptomeninges. 21 CAA diagnosis was made if vascular amyloid deposition (≥1 and ≥2 in Vonsattel's CAA severity scale for brain biopsy and full autopsy, respectively was documented.
HCHWA-D Mutation (Dutch Cohort)
DNA isolation and analysis for identification of presence/absence of E22Q point mutation within AβPP gene was performed in all participants. Methodology has been described in detail elsewhere. 
Imaging Acquisition and Analysis
MRI studies were obtained using 1.5T and 3T scanners. Sequences used in this study were T2-weighted fast spin echo, fluid-attenuated inversion recovery, and either T2*-gradient echo or susceptibilityweighted imaging. Imaging protocols and technical parameters of MRI sequences for both study cohorts have been described elsewhere. 19, 24 Microbleeds were defined as focal, small (<10 mm), round, or ovoid areas of marked signal-loss on either gradient echo or susceptibility-weighted imaging sequences, different from vascular flow voids, calcifications, cavernous malformations, and basal ganglia mineralization. On the same MRI sequences, intracerebral hemorrhages (ICHs) were defined as parenchymal defects, generally >10 mm, with evidence of hemosiderin deposition. Rating of microbleeds and ICHs was done after previously published guidelines. 25 White matter hyperintensities (WMH) volumes were quantified on fluid-attenuated inversion recovery sequences. We used a previously described method consisting of the substraction of a first layer of regions of interest corresponding to WMH created semiautomatically based on intensity thresholding, and a second layer of regions of interest manually outlined by gross contouring of all WMHs. 26 A slightly modified version of this method was used to calculate CSO-PVS relative volume on T2-weighted fast spin echo images. The PVS segmentation technique comprised the following steps: (1) selection of the first brain slice immediately above the lateral ventricles; (2) adjustment of brightness and contrast to highlight PVS against the WM in the background; (3) thresholding and creation of an intensity-based mask that includes as many visible PVS as possible; (4) drawing manually a second mask over areas of the WM containing dilated PVS; (5) subtraction of both masks; and (6) manual correction of the resulting mask to ensure that it contains only PVS. As the plane of MRI acquisition and other factors could substantially modify the volume of brain where PVS were assessed from subject to subject, we adjusted the absolute PVS volume by the intracranial volume in the measured slice. Final CSO-PVS relative volume for each individual was expressed as a percentage of the intracranial volume in that slice that corresponded to CSO-PVS. The method for intracranial volume calculation was also based on thresholding and mask subtraction. Figure 2 provides a visual example of the process. Although CSO-PVS and intracranial volumes were generally determined in both hemispheres, cases with ICH distorting CSO required measurements to be done in the unaffected side only, and then multiplied by 2 assuming symmetrical PVS burden.
Last, PVS in the basal ganglia were rated on axial T2-weighted fast spin echo images, using a previously described validated 4-point visual rating scale (0, no PVS; 1, <10 PVS; 2, 11-20 PVS; 3, 21-40 PVS; and 4, 40 PVS) 27 and following Standards for ReportIng Vascular Changes on Neuroimaging (STRIVE) definitions. 28 We dichotomized basal ganglia PVS burden in low (degrees 0, 1, and 2) and high (degrees 3 and 4) as in previous analyses. 14 Rating of microbleed and quantitative analyses of WMH, PVS, and intracranial structures were assisted by the image processing software MRIcron (http://people.cas.sc.edu/rorden/mricron/install. html). All neuroimaging ratings at MGH and Leiden Medical Center were performed by expert readers blind to the subjects' demographics, clinical characteristics, and neuropathological/genetic findings. We have previously reported a very high interrater reliability for microbleed detection 29 and WMH volume quantification. 26 Intraclass correlation coefficient for CSO-PVS relative volume measurement between MGH and Leiden readers (Drs Martinez-Ramirez and van Rooden, respectively) >14 scans was excellent (0.93).
Clinical Variables and Subclassification of Study Subjects
For each individual in both cohorts, we collected age at the time of MRI study, sex and presence of hypertension (defined as a diagnosis of hypertension and use of antihypertensive drugs based on medical records review).
Patients from the hospital-based cohort were initially classified by neuropathology into non-CAA (CAA 
Standard Protocol Approvals, Registrations, and Patient Consents
The study was approved at MGH and Leiden University Medical Center by the local Institutional Review Board and the local ethics committee, respectively. 
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Written informed consent was obtained from all subjects enrolled in the Leiden prospective cohort. MGH subjects (or their surrogates) had consented in the past to brain biopsy or autopsy for clinical and research purposes but were not requested additional consent for the present study given the retrospective nature of it and the anonymized treatment of data.
Statistics
CSO-PVS relative volume was compared between CAA and non-CAA subjects and between HCHWA-D carriers and noncarriers using the median test (non-normal continuous variable). Other variables were compared with the Wilcoxon test, Student t test (normal continuous variables), and Fisher exact test (proportions). To compare CSO-PVS relative volume between the 3 diagnostic categories (CAA -, CAA+/H -, and CAA+/H+) in the hospital cohort, we used 3-way ANOVA test to look for global differences, and Wilcoxon test to explore differences by pairs. Besides CSO-PVS relative volume, all variables reaching a global P value <0.1 in bivariate analyses were selected to enter logistic regression models.
Nominal logistic regression models were used to study whether increased CSO-PVS relative volume is independently associated with the presence (yes/no) of sporadic CAA and HCHWA-D carrier status (dependent variables). To study whether CSO-PVS relative volume may be predictive of sporadic CAA in the absence of hemorrhage, the multiple diagnostic classification (CAA -versus CAA+/H -versus CAA+/H+) was chosen as the dependent variable and alternative regression strategy was applied: multiple nominal logistic regressions, excluding one of the diagnostic categories at a time.
Significance level was set at 0.05 and all tests of significance were 2-tailed. JMP Pro 10 (SAS Institute, Cary, NC) and Stata 11.2 (StataCorp, College Station, TX) software were used for data analysis.
Results
The sporadic CAA cohort consisted of 63 individuals (mean age, 73.6±8.5 years; 46% female) and the Dutch cohort consisted of 54 individuals (mean age, 46.7±12.8 years; 61.1% female). Table 1 shows the basic demographics for each study cohort.
CSO-PVS relative volume was significantly higher in patients with sporadic CAA compared with those without. Similarly, HCHWA-D mutation carriers had significantly higher CSO-PVS relative volume than noncarriers ( (Table 4) . 
Discussion
In this study, we demonstrated increased PVS (specifically in the CSO region) in CAA patients with pathologicallyproven sporadic CAA as well as genetic Dutch-type CAA. The consistent results in the younger hereditary CAA cohort in addition to the older sporadic CAA, suggest that increased MRI-visible CSO-PVS are a characteristic marker of the disease independent of additional factors, including advanced age. Additionally, we showed that high CSO-PVS volume is an independent predictor of neuropathologicallydefined sporadic CAA even in the absence of lobar hemorrhages (microbleed or ICH), which supports its potential utility in the diagnosis of nonhemorrhagic or even early forms of the disease.
Sporadic CAA is the form of amyloid angiopathy that accounts for the vast majority of CAA cases in the elderly. 30 The Boston Criteria rely on the presence of strictly lobar hemorrhages for the clinical diagnosis of CAA. 18, 31 Little additional diagnostic value is gained when superficial siderosis is also incorporated in the criteria. 32 Validation studies of the Boston criteria have overall shown the need for new markers to improve their sensitivity, which is estimated to be only around 42% to 63%. 21, 33 The present study provides preliminary evidence for CSO-PVS volume as an independent marker for the diagnosis of sporadic CAA and may be a useful marker to be further explored in larger studies.
PVS in basal ganglia regions have been typically linked to hypertension. 14, 34 Although increased PVS in WM areas have been repeatedly associated to CAA markers across different populations, 14, 15 recent work has also reported associations with hypertension and markers of hypertensive vasculopathy. 20, 35 This suggests the potential for overlapping etiologies and risk factors contributing to CSO-PVS, for which it may be difficult to dissect their independent role. The importance of the finding of increased CSO-PVS in HCHWA-D mutation carriers lies in the fact that the younger age of these patients (mean age, 45.8 years) virtually excludes the impact of prolonged exposure to vascular risk factors on PVS dilation. Thus, in this cohort, vascular Aβ emerges as the main single suspect associated with PVS dilation in CSO.
Another valuable aspect of finding increased CSO-PVS volumes in both hereditary and sporadic CAA relates to our understanding of the mechanisms leading to PVS dilation. The pathophysiology of the Dutch-type amyloidosis is mainly driven by the production of toxic amyloid species, with enhanced fibrillogenic properties, and resistance to enzymatic degradation. [36] [37] [38] This allows us to speculate that in these young HCHWA-D mutation carriers, the increased PVS dilation seen in CSO may be simply a direct consequence of extensive perivascular amyloid deposition in the cortex, with secondary retrograde dilation of PVS into the WM. Interestingly, this hypothesis of cortical PVS blockage by amyloid had been previously postulated for sporadic CAA in Alzheimer disease patients. 7 It is possible that multiple mechanisms contribute to PVS dilation in the CSO in the elderly. It is conceivable that increased PVS dilation in the WM may be a surrogate of chronic poor perivascular drainage caused by aging and exposure to vascular risk factors, which predisposes individuals to amyloid stagnation and CAA development. This hypothesis would align with the current concept of sporadic CAA as a result of cumulative age-related defects in amyloid clearance pathways. 6 The use of both pathologically and genetically confirmed cases from 2 different types of CAA respectively, and the application of a novel quantitative method to estimate CSO-PVS burden are the main strengths of this study. This method allowed for a continuous quantification of PVS burden, not subjected to the arbitrary thresholds of visual scales used in earlier studies. 27, 39 In populations like the ones studied here, quantitative measurements may be more useful than visual scales because they avoid potential ceiling effects. Our study has some limitations. The hospital cohort was retrospective, 
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and thus some radiological studies were obtained at 1.5T MRI, which depicts tiny structures like PVS with less resolution and may have resulted in systematically lower volumes in a subset of patients. However, the fact that the same associations were present in the Dutch cohort, which included a homogenous 3T MRI protocol, is reassuring. Our method to quantitatively assess CSO-PVS has excellent interrater reliability. However, we note that this tool might have somewhat limited applicability in a clinical setting as it is time-consuming and requires good quality imaging sequences. Also, it is uncertain whether CSO-PVS are a consistent good estimator of the whole PVS load in the brain, or at least in the WM. Standardized, fully automated and reliable whole brain assessment techniques for PVS volume quantification are desirable and should be developed in the near future to further improve generalizability of results in the PVS field.
40
Conclusions
Increased CSO-PVS volume is found in both hereditary and sporadic forms of amyloid angiopathy, and seems a promising marker of sporadic CAA, even in the absence of any lobar hemorrhages. Whether PVS volume increases early in the disease course, or even before any vascular Aβ accumulates, is currently unknown. Prospective, population-based neuroimaging studies are needed to clarify these important questions.
Sources of Funding
This study was supported by the following National Institutes of Health grants: R01 NS070834, R01AG047975, R01AG026484, P50AG005134, and K23AG02872605. Dr Wermer was supported by a personal grant from the Netherlands Heart Foundation.
Disclosures
None.
